HolderBook

DIADEMA PARTNERS LP

Reported holdings as of Q2 2026, from 7 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
2026172
Reported value
$791.3M
Positions
116
Top 10 weight
50.4%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
ABIVAX SA CALL+PUTABVX$101.8M163,64412.86%+7.67pp4q+115.5%+$54.5M
VIKING THERAPEUTICS INC CALL+PUTVKTX$78.5M441,8089.92%+3.37pp6q-15.9%-$14.8M
BRISTOL-MYERS SQUIBB CO CALL+PUTBMY$53.6Moptions only6.78%-newOPTIONS
UNITED THERAPEUTICS CORP DELUTHR$28.7M52,9893.63%-5.20pp3q+94.1%+$13.9M
REVOLUTION MEDICINES INCRVMD$26.1M139,2183.29%-0.12pp5q+72.1%+$10.9M
UNIQURE NV CALL+PUTQURE$24.6Moptions only3.11%+1.50pp7qOPTIONS
NOVARTIS AG CALL+PUTNVS$23.5Moptions only2.97%-newOPTIONS
KODIAK SCIENCES INC CALL+PUTKOD$21.9M218,1172.77%-0.09pp4q+13.0%+$2.5M
CAPRICOR THERAPEUTICS INC CALL+PUTCAPR$20.8Moptions only2.63%-2.71pp7qOPTIONS
COGENT BIOSCIENCES INCCOGT$19.1M493,6642.41%+0.30pp7q+52.9%+$6.6M
BRIDGEBIO PHARMA INC$18.6M250,0002.35%-0.81pp2qDEBT
CORCEPT THERAPEUTICS INC CALLCORT$17.9Moptions only2.27%+1.11pp6qOPTIONS
BIOMARIN PHARMACEUTICAL INCBMRN$17.9M312,8462.26%+0.84pp6q+111.1%+$9.4M
KYMERA THERAPEUTICS INC CALLKYMR$17.2Moptions only2.17%-newOPTIONS
SUMMIT THERAPEUTICS INC CALL+PUTSMMT$16.3M60,0002.06%-newNEW
HIMS & HERS HEALTH INC CALL+PUTHIMS$13.6Moptions only1.72%-newOPTIONS
REPLIMUNE GROUP INC CALL+PUTREPL$13.3Moptions only1.68%+0.68pp7qOPTIONS
BIOGEN INC CALLBIIB$13.0Moptions only1.64%-newOPTIONS
ELI LILLY & CO PUTLLY$12.0Moptions only1.52%+0.58pp6qOPTIONS
INCYTE CORP PUTINCY$11.9Moptions only1.51%-1.43pp4qOPTIONS
EDGEWISE THERAPEUTICS INCEWTX$11.1M272,2141.40%+0.26pp3qHELD
ARCUS BIOSCIENCES INC CALLRCUS$10.7M223,8101.36%+0.48pp2q-6.0%-$686.7K
BIONTECH SE CALLBNTX$9.3Moptions only1.18%-newOPTIONS
CORBUS PHARMACEUTICALS HLDGS CALLCRBP$8.8M301,2641.11%+0.22pp2q-31.5%-$4.0M
VAXCYTE INC CALL+PUTPCVX$8.5M45,0711.08%+0.31pp7q+79.8%+$3.8M
BIOAGE LABS INC CALLBIOA$8.5M146,3341.07%+0.89pp3q+143.9%+$5.0M
IMMUNOCORE HLDGS PLCIMCR$8.1M254,8631.02%+0.03pp6q+31.9%+$2.0M
4D MOLECULAR THERAPEUTICS INFDMT$7.6M571,1070.96%-newNEW
NOVO-NORDISK A S PUTNVO$7.5M100,0000.95%+0.51pp6q+586.0%+$6.4M
SELLAS LIFE SCIENCES GROUP I CALL+PUTSLS$7.4Moptions only0.93%+0.72pp5qOPTIONS
MODERNA INC PUTMRNA$7.0Moptions only0.88%-0.49pp2qOPTIONS
CORVUS PHARMACEUTICALS INC CALLCRVS$6.4M294,8110.81%-0.07pp4q+20.4%+$1.1M
MONTE ROSA THERAPEUTICS INC CALLGLUE$6.0M78,3910.76%+0.24pp3q-58.1%-$8.4M
ALUMIS INC CALLALMS$5.6Moptions only0.71%+0.22pp2qOPTIONS
ROYALTY PHARMA PLC CALLRPRX$5.6Moptions only0.71%-newOPTIONS
JOHNSON & JOHNSONJNJ$5.6M22,0000.71%-1.53pp3q-59.1%-$8.1M
UNICYCIVE THERAPEUTICS INC CALLUNCY$5.1M303,6760.65%+0.53pp2q+186.3%+$3.3M
CELLDEX THERAPEUTICS INC NEW CALL+PUTCLDX$5.1Moptions only0.64%-newOPTIONS
BIOHAVEN LTD CALLBHVN$4.7Moptions only0.60%+0.14pp3qOPTIONS
VERA THERAPEUTICS INC PUTVERA$4.6M57,6080.58%-newNEW
TENAX THERAPEUTICS INC CALLTENX$4.5Moptions only0.56%+0.08pp3qOPTIONS
RELAY THERAPEUTICS INCRLAY$4.3M230,6770.55%-newNEW
TG THERAPEUTICS INC CALLTGTX$4.2Moptions only0.53%-0.64pp7qOPTIONS
AMGEN INC CALLAMGN$3.8M102,7010.48%-newNEW
ZYMEWORKS INCZYME$3.7M142,1320.47%-0.14pp6qHELD
TAYSHA GENE THERAPIES INCTSHA$3.6M522,6190.45%-newNEW
INTELLIA THERAPEUTICS INC CALLNTLA$3.4Moptions only0.43%-0.01pp4qOPTIONS
NURIX THERAPEUTICS INCNRIX$2.9M121,5390.37%-newNEW
INDIVIOR PHARMACEUTICALS INCINDV$2.8M67,5120.35%-0.02pp2q-5.4%-$158.5K
INVENTIVA SAIVA$2.7M740,7860.34%+0.02pp3q+110.2%+$1.4M
ORUKA THERAPEUTICS INCORKA$2.6M27,7990.33%-newNEW
CYTOKINETICS INC PUTCYTK$2.6Moptions only0.32%-2.48pp2qOPTIONS
RELMADA THERAPEUTICS INCRLMD$2.5M361,3670.32%+0.08pp3q+79.9%+$1.1M
ANNEXON INC CALLANNX$2.2M27,5160.27%-0.18pp3q-79.3%-$8.3M
CELCUITY INC CALLCELC$2.1Moptions only0.26%-0.18pp2qOPTIONS
SEPTERNA INC PUTSEPN$2.0Moptions only0.25%+0.25pp2qOPTIONS
CYBIN INC CALLHELP$2.0M200,0000.25%-newNEW
VOYAGER THERAPEUTICS INC CALLVYGR$2.0M413,6420.25%-0.13pp2q-2.4%-$47.7K
CONTINEUM THERAPEUTICS INCCTNM$2.0M119,7330.25%-newNEW
BICYCLE THERAPEUTICS PLCBCYC$2.0M462,7240.25%-0.13pp2q-2.9%-$58.1K
VIRIDIAN THERAPEUTICS INCVRDN$1.8M100,0000.23%-newNEW
MACROGENICS INCMGNX$1.7M374,4030.22%-0.08pp2q-37.6%-$1.0M
PROQR THRAPEUTICS N VPRQR$1.7M926,0160.22%+0.17pp7q+414.2%+$1.4M
ADMA BIOLOGICS INC CALLADMA$1.7Moptions only0.21%-newOPTIONS
SPRUCE BIOSCIENCES INCSPRB$1.6M30,0000.20%+0.09pp2q+200.0%+$1.1M
ARDELYX INCARDX$1.5M303,0250.20%-newNEW
CUE BIOPHARMA INC CALLCUE$1.5M48,3690.19%-newNEW
MINERALYS THERAPEUTICS INCMLYS$1.5M56,3470.19%+0.07pp3q+113.9%+$809.4K
EYEPOINT INC CALLEYPT$1.5Moptions only0.19%-0.43pp2qOPTIONS
PROTHENA CORP PLCPRTA$1.5M149,4820.18%-newNEW
PHATHOM PHARMACEUTICALS INCPHAT$1.4M129,9500.18%+0.07pp2q+137.8%+$817.0K
EVOLUS INC CALLEOLS$1.4Moptions only0.18%+0.09pp3qOPTIONS
SPYRE THERAPEUTICS INCSYRE$1.3M15,0000.17%-newNEW
CORMEDIX INC PUTCRMD$1.3Moptions only0.17%-0.03pp4qOPTIONS
EDITAS MEDICINE INC CALLEDIT$1.3Moptions only0.16%-newOPTIONS
EQUILLIUM INCEQ$1.3M400,2820.16%+0.01pp4q-7.7%-$107.4K
PYXIS ONCOLOGY INC CALLPYXS$1.2Moptions only0.15%-newOPTIONS
XERIS BIOPHARMA HOLDINGS INCXERS$1.1M132,7460.13%flat4qHELD
PHARVARIS N VPHVS$1.0M29,3210.13%-0.01pp2qHELD
HARMONY BIOSCIENCES HLDGS INHRMY$978.1K26,8640.12%-0.32pp4q-71.1%-$2.4M
CARTESIAN THERAPEUTICS INCRNAC$907.1K87,0570.11%-newNEW
AQUESTIVE THERAPEUTICS INC CALLAQST$892.7Koptions only0.11%-newOPTIONS
RIGEL PHARMACEUTICALS INCRIGL$892.6K22,8160.11%-newNEW
ELICIO THERAPEUTICS INC CALL+PUTELTX$829.3Koptions only0.10%-newOPTIONS
PRECIGEN INCPGEN$771.2K135,2930.10%+0.06pp2q+144.7%+$456.0K
DEFINIUM THERAPEUTICS INCDFTX$726.8K15,4510.09%-newNEW
PELTHOS THERAPEUTICS INCPTHS$700.1K24,7730.09%flat4qHELD
PEPGEN INCPEPG$671.9K373,2840.08%+0.04pp2q+147.3%+$400.2K
CG ONCOLOGY INC CALLCGON$518.7Koptions only0.07%-newOPTIONS
ENLIVEN THERAPEUTICS INCELVN$507.5K10,0000.06%+0.06pp2q+3981.6%+$495.1K
CONNECT BIOPHARMA HLDGS LTDCNTB$468.8K196,9850.06%-0.03pp2q-1.8%-$8.8K
LARIMAR THERAPEUTICS INCLRMR$447.2K146,6370.06%-0.07pp2q-12.0%-$61.0K
CELLECTAR BIOSCIENCES INCCLRB$384.6K138,3410.05%-newNEW
FOGHORN THERAPEUTICS INCFHTX$326.5K66,9080.04%-0.02pp4q-16.3%-$63.6K
AYTU BIOPHARMA INCAYTU$319.4K148,5460.04%-0.12pp4q-57.9%-$439.7K
OCUGEN INCOCGN$306.0K200,0000.04%-0.12pp2qHELD
INOVIO PHARMACEUTICALS INC CALLINO$302.7Koptions only0.04%-0.15pp3qOPTIONS
UROGEN PHARMA LTDURGN$262.6K7,1370.03%-0.04pp7q-69.2%-$589.5K
HERON THERAPEUTICS INCHRTX$195.8K458,7230.02%-newNEW
TALPHERA INCTLPH$158.2K153,5630.02%flat3qHELD
MONOPAR THERAPEUTICS INCMNPR$150.9K1,6300.02%flat2qHELD
LAKELAND INDS INCLAKE$150.8K14,1080.02%-newNEW
UPSTREAM BIO INCUPB$132.1K19,0930.02%-0.02pp4q-11.6%-$17.4K
MEIRAGTX HLDGS PLC CALLMGTX$119.8K8,3680.02%-newNEW
JATT II ACQUISITION CORP$102.5K9,0210.01%-newNEW
KAILERA THERAPEUTICS INCKLRA$79.8K3,6210.01%-newNEW
MANNKIND CORPMNKD$68.2K16,0030.01%-0.07pp6q-91.4%-$726.8K
ENTERA BIO LTDENTX$41.2K23,2600.01%flat2qHELD
ARS PHARMACEUTICALS INCSPRY$38.9K4,8600.00%-newNEW
APREA THERAPEUTICS INCAPRE$36.0K44,9070.00%-newNEW
TVARDI THERAPEUTICS INCTVRD$31.6K16,6070.00%-newNEW
VISTAGEN THERAPEUTICS INC CALLVTGN$13.0Koptions only0.00%-0.01pp7qOPTIONS
NEXTCURE INCNXTC$12.4K7,7420.00%-newNEW
ATYR PHARMA INC PUTATYR$7.5Koptions only0.00%flat6qOPTIONS
JADE BIOSCIENCES INC PUTJBIO$3.2Koptions only0.00%flat4qOPTIONS
ERASCA INC CALLERAS$1.8Koptions only0.00%-newOPTIONS

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 95.6%Healthcare Services 2.0%Other sectors 0.0%Not classified 2.4%
 
SectorValueShare
Biotech & Pharma$756.7M95.6%
Healthcare Services$15.7M2.0%
Other sectors$150.8K0.0%
Not classified$18.8M2.4%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q3 2025+8.8%+7.8%+1.0%66%
Q1 2025-5.4%-4.6%-0.8%65%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$791.3M1164321323850.4%45
Q1 2026$587.7M1114424195250.5%45
Q4 2025$580.5M1194616233349.4%48
Q3 2025$391.0M106536222239.1%45
Q2 2025$328.2M752316152053.7%45
Q1 2025$383.3M723117104567.5%45
Q4 2024$233.1M86000051.8%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.